Post-exposure immunotherapy for two ebolaviruses and Marburg virus in nonhuman primates

Post-exposure immunotherapy for two ebolaviruses and Marburg virus in nonhuman primates

Current experimental monoclonal antibodies (mAbs) for Ebola virus (EBOV) post-exposure immunotherapy are ineffective against Sudan (SUDV) or Marburg virus (MARV). Here, authors develop cocktails of mAbs that protect nonhuman primates against EBOV, SUDV, and MARV infection when given four days post i...

Full description

Saved in:
Bibliographic Details
Main Authors: Jennifer M. Brannan, Shihua He, Katie A. Howell, Laura I. Prugar, Wenjun Zhu, Hong Vu, Sergey Shulenin, Shweta Kailasan, Henna Raina, Gary Wong, Md Niaz Rahim, Logan Banadyga, Kevin Tierney, Xuelian Zhao, Yuxing Li, Frederick W. Holtsberg, John M. Dye, Xiangguo Qiu, M. Javad Aman
Format: article
Language:EN
Published: Nature Portfolio 2019
Subjects:
Science
Q
Online Access:https://doaj.org/article/b99aa7a0e5ce4018ab41eac4e31287f3
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Current experimental monoclonal antibodies (mAbs) for Ebola virus (EBOV) post-exposure immunotherapy are ineffective against Sudan (SUDV) or Marburg virus (MARV). Here, authors develop cocktails of mAbs that protect nonhuman primates against EBOV, SUDV, and MARV infection when given four days post infection.

Similar Items